StreetInsider.com News Articles

Roth/MKM Starts Atrium Therapeutics (RNA) at Buy

Thu, 22 Oct 2026 02:31:29 -0400

Roth/MKM analyst Boobalan Pachaiyappan initiates coverage on Atrium Therapeutics (NASDAQ: RNA) with a Buy rating and a price target of $15.00.

The analyst comments: “We initiate coverage of Atrium Therapeutics with a Buy and $15 PT. Spun out following Novartis’ ~$12B Avidity acquisition, Atrium aims to extend targeted RNA delivery from skeletal muscle to the heart: PRKAG2 syndrome (ATR1072; Ph1/2; 25% PoA) and PLN cardiomyopathy (ATR1086; preclinical; 15% PoA). At $7.98 (10/20/26), RNA trades ~30% below our ~$11.38/share 4Q26E pro forma cash, including the $50M October PIPE. The post-DM1 selloff implies negative pipeline value; we believe FSHD could offer more relevant

Roth/MKM Starts Atrium Therapeutics (RNA) at Buy

Thu, 22 Oct 2026 02:31:29 -0400

Roth/MKM analyst Boobalan Pachaiyappan initiates coverage on Atrium Therapeutics (NASDAQ: RNA) with a Buy rating and a price target of $15.00.

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Tue, 20 Oct 2026 17:23:00 -0400

SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on October 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of one non-executive individual newly hired by the Company.

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Tue, 20 Oct 2026 17:23:00 -0400

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Tue, 20 Oct 2026 17:23:00 -0400

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Tue, 20 Oct 2026 17:23:00 -0400

Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing

Tue, 20 Oct 2026 08:09:00 -0400

Yakira urges Board to explore strategic alternatives before further cash burn and dilution erode shareholder value; questions decision to raise $50 million after shares fell approximately 44% at a valuation near fifty percent of net cash

WESTPORT, Conn., Oct. 20, 2026 /PRNewswire/ -- Yakira Capital Management, Inc. ("Yakira") a shareholder of Atrium Therapeutics, Inc. (NASDAQ: RNA), today called on

Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing

Tue, 20 Oct 2026 08:09:00 -0400

WESTPORT, Conn., Oct. 20, 2026 /PRNewswire/ -- Yakira Capital Management, Inc. ("Yakira") a shareholder of Atrium Therapeutics, Inc. (NASDAQ: RNA), today called on

Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing

Tue, 20 Oct 2026 08:09:00 -0400

WESTPORT, Conn., Oct. 20, 2026 /PRNewswire/ -- Yakira Capital Management, Inc. ("Yakira") a shareholder of Atrium Therapeutics, Inc. (NASDAQ: RNA), today called on

Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing

Tue, 20 Oct 2026 08:09:00 -0400

WESTPORT, Conn., Oct. 20, 2026 /PRNewswire/ -- Yakira Capital Management, Inc. ("Yakira") a shareholder of Atrium Therapeutics, Inc. (NASDAQ: RNA), today called on

Atrium Therapeutics (RNA) Reiterated at Overweight by Cantor Fitzgerald After Model Update

Thu, 15 Oct 2026 07:51:00 -0400

Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $25.00 price target on Atrium Therapeutics (NASDAQ: RNA).

The analyst commented, "We are updating our RNA model and providing our latest views on the stock following the recent $50M private placement, which is guided to extend cash runway through 2028 (from mid-2028). The financing allowed the company to not just extend its runway but get high-quality institutional investors involved, which is particularly important as the stock spun out in a unique way (from Avidity). With RNA shares currently trading at ~-$120M EV, we believe the Street is significantly undervaluing the company.

Atrium Therapeutics raises $50M in private placement

Thu, 08 Oct 2026 06:30:21 -0400

Atrium Therapeutics, Inc. (Nasdaq: RNA), a biopharmaceutical company focused on RNA therapeutics for cardiac conditions, announced a $50 million private placement with a group of institutional investors.

The financing includes 5,170,384 shares of common stock priced at $7.93 per share and pre-funded warrants to purchase up to 1,134,930 shares at $7.929 per warrant. The private placement was priced at-the-market under Nasdaq rules and was expected to close on or about Oct. 9, 2026, subject to customary closing conditions.

Participating investors include Sirenia Capital Management LP, Aberdeen Investments, Montanova, Sessa Capital, Casdin Capital, and a life sciences-focused institutional investor, among others.

The company said

Atrium Therapeutics Announces $50 Million Private Placement

Thu, 08 Oct 2026 06:30:00 -0400

SAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that it has entered into a securities purchase agreement (the "purchase agreement") with a group of leading institutional investors for a private placement financing (the "private placement"). The private placement is expected to result in aggregate gross proceeds to the Company of approximately

Atrium Therapeutics Announces $50 Million Private Placement

Thu, 08 Oct 2026 06:30:00 -0400

Atrium Therapeutics Announces $50 Million Private Placement

Thu, 08 Oct 2026 06:30:00 -0400

Atrium Therapeutics Announces $50 Million Private Placement

Thu, 08 Oct 2026 06:30:00 -0400

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Mon, 21 Sep 2026 16:30:00 -0400

SAN DIEGO, Sept. 21, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on September 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of one non-executive individual newly hired by the Company.

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Mon, 21 Sep 2026 16:30:00 -0400

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Mon, 21 Sep 2026 16:30:00 -0400

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Mon, 21 Sep 2026 16:30:00 -0400

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)